<?xml version="1.0" encoding="UTF-8"?>
<p class="p">It is currently accepted that supplementation with n-3 LCPUFAs might improve some metabolic syndrome features such as insulin resistance, hypertension, and dyslipidemia, mainly by decreasing plasma triglycerides. Several meta-analyses have confirmed that the most consistent action of Ï‰3 LCPUFAs is the reduction in triglycerides [
 <xref rid="B27-ijms-20-02118" ref-type="bibr" class="xref">27</xref>]. 
</p>
